Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Moderna

Australia risks relying on Pfizer and Moderna for its COVID vaccines. 3 ways to break free

The rapid development and deployment of COVID vaccines has been one of the greatest achievements of the pandemic.

The Conversation

Biden administration and GOP clash over vaccine strategy

Biden administration and GOP clash over vaccine strategy

The administration wants to keep access as open as possible, but the GOP wants to reduce wastage.

Why Did Moderna CFO Exit Just A Day After Taking Charge

Why Did Moderna CFO Exit Just A Day After Taking Charge

Moderna Inc (NASDAQ:MRNA) announced that its recently appointed Chief Financial Officer, Jorge Gomez, has departed the company, effective immediately. The announcement follows the public disclosure by Gomez's former employer, Dentsply Sirona Inc (NASDAQ:XRAY), of an ongoing internal investigation into some issues, including financial reporting. The audit investigates Dentsply Sirona's "use of incentives to sell products to…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Why Moderna Shares Are Trading Lower Following Novavax's Earnings Report

Moderna Inc (NASDAQ: MRNA) shares are trading lower by 3.15% at $131.52.

Fourth Covid booster vaccine 'significantly' improves protection over just three jabs

It is "over and above" the level of protection that people who have had their third jab receive, according to the latest research.

Covid vaccines safe for pregnant women and cut stillbirth risk, says review

Chance of stillbirth reduced by 15%, researchers find, after examining studies and trials that enrolled 117,552 women

The Guardian - UK

Fourth booster ‘significantly’ increases Covid protection

Levels of antibodies waned in period between third jabs and fourth boosters

inkl

Read news from The Economist, FT, and more,
with one subscription

Covid: ‘Vaccine ceiling’ approaching for some as study suggests fourth jab may not be necessary

Covid: ‘Vaccine ceiling’ approaching for some as study suggests fourth jab may not be necessary

A ‘hint’ that some people might have already reached ‘ceiling’ in terms of protection they could acquire from fourth jab

The Independent UK

Morning Brief: Top Financial Stories Dominating on Monday, May 9

Morning Brief: Top Financial Stories Dominating on Monday, May 9

CNBC Ford Motor Selling 8M Shares Of Rivian Automotive

Moderna Files Motion To Dismiss COVID-19 Vaccine Related Patent Claims: WSJ

Moderna Files Motion To Dismiss COVID-19 Vaccine Related Patent Claims: WSJ

Moderna Inc (NASDAQ: MRNA) is trying to fight off rival companies’ patent infringement claims related to its COVID-19 vaccine, arguing that the companies may only pursue their claims by seeking royalties from the federal government.

Looking At Moderna's Recent Whale Trades

Looking At Moderna's Recent Whale Trades

Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

US Drug Regulator Limits Use of J&J Covid Vaccine

US Drug Regulator Limits Use of J&J Covid Vaccine

The US said Thursday only adults who "have personal concerns" about mRNA vaccines, access issues or medical reasons for refusing them may now receive the Johnson & Johnson Covid shot, which has been linked to a rare but serious clotting condition. The vaccine, which was authorized as a single shot,…

Asharq Al-Awsat

Check Out What Whales Are Doing With MRNA

Check Out What Whales Are Doing With MRNA

Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Where Moderna Stands With Analysts

Where Moderna Stands With Analysts

Analysts have provided the following ratings for Moderna (NASDAQ:MRNA) within the last quarter:

Get all your
news in one place.

100's of premium titles.
One news app.

Los Angeles Times

Commentary: COVID won’t become endemic until we have a vaccine for kids under 5

Last week, Moderna became the first manufacturer to officially ask the Food and Drug Administration to approve its COVID-19 vaccine for children under 6 years old. One of three companies with authorized COVID-19 vaccines in the United States, Moderna made the request a month after saying its data showed efficacy…

Mid-Day Market Update: Dow Rises 100 Points; Lyft Shares Plummet

U.S. stocks traded mixed midway through trading, with the Dow Jones gaining more than 100 points on Wednesday.

Mid-Morning Market Update: Markets Mixed; Nasdaq Tumbles 100 Points

U.S. stocks traded mixed this morning, with the Nasdaq dropping more than 100 points on Wednesday.

The Conversation

Will new vaccines be better at fighting coronavirus variants? 5 questions answered

The first three coronavirus vaccines earned Emergency Use Authorization more than a year ago. To date, no other vaccines have been put into use in the U.S – but that will soon change. More than 40 vaccines are undergoing clinical trials in the U.S., employing a number of different approaches…

Get all your
news in one place.

100's of premium titles.
One news app.

Here's Why Moderna Shares Are Trading Higher After Q1 Earnings Today

Moderna Inc (NASDAQ:MRNA) reports a Q1 EPS of $8.58, compared to the $2.84 posted a year ago, handsomely beating the consensus estimate of $5.21. Total revenue was $6.1 billion compared to $1.9 billion in Q1 FY21, primarily due to increased product sales. The revenue consensus was $4.43 billion. Product sales were $5.9…

Moderna: Q1 Earnings Insights

Moderna (NASDAQ:MRNA) reported its Q1 earnings results on Wednesday, May 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

The Independent UK

Pfizer hopes to submit little-kid vaccine data by early June

Pfizer now hopes to tell U.S. regulators how well its COVID-19 vaccine works in the littlest kids by early June

The Guardian - UK

Pfizer accused of Covid profiteering as first-quarter sales hit $26bn

Pharma firm criticised over pricing and for keeping monopoly control over vaccine and new Paxlovid pill

Moderna Bullish On COVID-19 Vaccine For Younger Kids To Be Ready Next Month: Reuters

Moderna Inc's (NASDAQ:MRNA) chief medical officer said that its COVID-19 vaccine for children under six years old would be ready for review by the FDA panel when it meets in June. "I think the FDA now has all of the core fundamental data they need to be able to begin an application review.…

Here's What To Watch On Moderna As The Stock Flies Higher

Moderna, Inc (NASDAQ: MRNA) was trading over 8% higher at one point on Monday morning, bouncing up within a descending channel pattern on the daily chart.

American Express And 2 Other Stocks Insiders Are Selling

Gold futures traded lower by around 2.5% on Monday. Investors, meanwhile, focused on some notable insider trades.

1 … 26 27 28 29

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Republican Party

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Intellectual Property

Places

407,103 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play